Fingya (Fingolimod) can affect patients with liver impairment. The exposure to Fingya is increased in patients with severe hepatic impairment, and the risk of adverse reactions may be greater in these patients. Therefore, patients with severe hepatic impairment should be closely monitored. Patients with liver disease should discuss the use of Fingya with their healthcare provider, and regular monitoring may be necessary to ensure the safe use of the medication.
